| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Arthritis, Juvenile | 53 | 2019 | 70 | 4.600 |
Why?
|
| Antirheumatic Agents | 16 | 2019 | 59 | 1.770 |
Why?
|
| Rheumatology | 6 | 2019 | 46 | 1.100 |
Why?
|
| Methotrexate | 9 | 2019 | 91 | 0.930 |
Why?
|
| Fibromyalgia | 8 | 2014 | 29 | 0.780 |
Why?
|
| Glucocorticoids | 8 | 2019 | 222 | 0.780 |
Why?
|
| Rheumatic Diseases | 5 | 2016 | 35 | 0.770 |
Why?
|
| Child | 75 | 2019 | 6405 | 0.720 |
Why?
|
| Adolescent | 60 | 2019 | 8912 | 0.520 |
Why?
|
| Immunosuppressive Agents | 5 | 2019 | 514 | 0.470 |
Why?
|
| Quality of Health Care | 3 | 2016 | 322 | 0.450 |
Why?
|
| Dermatomyositis | 6 | 2017 | 31 | 0.430 |
Why?
|
| Pyoderma Gangrenosum | 1 | 2010 | 7 | 0.370 |
Why?
|
| Severity of Illness Index | 14 | 2009 | 1851 | 0.360 |
Why?
|
| Humans | 102 | 2023 | 68618 | 0.360 |
Why?
|
| Child, Preschool | 34 | 2019 | 3187 | 0.360 |
Why?
|
| Pain Measurement | 10 | 2014 | 328 | 0.360 |
Why?
|
| Cicatrix | 1 | 2010 | 60 | 0.350 |
Why?
|
| Uveitis | 3 | 2019 | 13 | 0.350 |
Why?
|
| Lupus Erythematosus, Systemic | 7 | 2009 | 756 | 0.340 |
Why?
|
| Enthesopathy | 2 | 2019 | 2 | 0.340 |
Why?
|
| Sacroiliitis | 2 | 2019 | 2 | 0.340 |
Why?
|
| Surveys and Questionnaires | 14 | 2017 | 2800 | 0.330 |
Why?
|
| Pediatric Assistants | 1 | 2008 | 3 | 0.320 |
Why?
|
| Macrophage Activation | 4 | 2007 | 75 | 0.320 |
Why?
|
| Disability Evaluation | 10 | 2014 | 298 | 0.280 |
Why?
|
| Clinical Medicine | 1 | 2006 | 20 | 0.280 |
Why?
|
| Male | 61 | 2019 | 37321 | 0.270 |
Why?
|
| Tumor Necrosis Factor-alpha | 5 | 2019 | 626 | 0.270 |
Why?
|
| Primary Ovarian Insufficiency | 1 | 2006 | 3 | 0.270 |
Why?
|
| Myositis | 6 | 2008 | 24 | 0.270 |
Why?
|
| Female | 64 | 2019 | 38074 | 0.270 |
Why?
|
| Teaching | 2 | 2006 | 169 | 0.260 |
Why?
|
| Faculty, Medical | 1 | 2006 | 110 | 0.260 |
Why?
|
| Cyclophosphamide | 2 | 2006 | 129 | 0.260 |
Why?
|
| Academic Medical Centers | 2 | 2008 | 281 | 0.260 |
Why?
|
| Medically Uninsured | 1 | 2006 | 99 | 0.260 |
Why?
|
| Infliximab | 3 | 2019 | 16 | 0.260 |
Why?
|
| Insurance, Health | 1 | 2006 | 201 | 0.240 |
Why?
|
| Sickness Impact Profile | 2 | 2013 | 27 | 0.240 |
Why?
|
| Withholding Treatment | 3 | 2019 | 35 | 0.230 |
Why?
|
| Acute-Phase Proteins | 3 | 2009 | 13 | 0.230 |
Why?
|
| Medicaid | 1 | 2006 | 302 | 0.230 |
Why?
|
| Child Behavior | 2 | 2003 | 56 | 0.230 |
Why?
|
| Social Adjustment | 2 | 2003 | 74 | 0.230 |
Why?
|
| Vasculitis | 1 | 2023 | 33 | 0.220 |
Why?
|
| Etanercept | 2 | 2017 | 12 | 0.220 |
Why?
|
| Cyclosporine | 3 | 2006 | 121 | 0.210 |
Why?
|
| Health Status | 6 | 2012 | 429 | 0.210 |
Why?
|
| Liver | 2 | 1999 | 1118 | 0.210 |
Why?
|
| src-Family Kinases | 1 | 2023 | 91 | 0.210 |
Why?
|
| Depression | 4 | 2014 | 943 | 0.200 |
Why?
|
| Adolescent Behavior | 2 | 2003 | 264 | 0.190 |
Why?
|
| Proto-Oncogene Proteins | 3 | 2009 | 411 | 0.190 |
Why?
|
| Health Services Accessibility | 1 | 2006 | 581 | 0.190 |
Why?
|
| Lupus Nephritis | 3 | 2008 | 193 | 0.190 |
Why?
|
| Occupational Therapy | 2 | 2019 | 80 | 0.190 |
Why?
|
| Biological Products | 2 | 2019 | 78 | 0.190 |
Why?
|
| Autoantibodies | 3 | 2018 | 434 | 0.190 |
Why?
|
| Physical Therapy Modalities | 2 | 2019 | 133 | 0.190 |
Why?
|
| Arthritis | 4 | 2019 | 53 | 0.190 |
Why?
|
| Quality of Life | 7 | 2013 | 1515 | 0.190 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 3 | 2019 | 240 | 0.180 |
Why?
|
| Drug Therapy, Combination | 4 | 2018 | 649 | 0.180 |
Why?
|
| Lipocalins | 3 | 2009 | 7 | 0.180 |
Why?
|
| Synovial Fluid | 4 | 2004 | 16 | 0.180 |
Why?
|
| Adaptation, Psychological | 3 | 2014 | 447 | 0.180 |
Why?
|
| Mood Disorders | 3 | 2010 | 132 | 0.170 |
Why?
|
| Endothelial Cells | 1 | 2023 | 384 | 0.170 |
Why?
|
| Treatment Outcome | 14 | 2019 | 7029 | 0.170 |
Why?
|
| S100A12 Protein | 1 | 2019 | 1 | 0.170 |
Why?
|
| Calgranulin B | 1 | 2019 | 2 | 0.170 |
Why?
|
| Calgranulin A | 1 | 2019 | 5 | 0.170 |
Why?
|
| Ophthalmology | 1 | 2019 | 39 | 0.160 |
Why?
|
| Sexual Behavior | 1 | 2000 | 183 | 0.160 |
Why?
|
| Risk-Taking | 1 | 2000 | 210 | 0.160 |
Why?
|
| Biopsy | 5 | 2010 | 540 | 0.160 |
Why?
|
| Emotions | 1 | 2000 | 244 | 0.160 |
Why?
|
| Poly-ADP-Ribose Binding Proteins | 1 | 2018 | 7 | 0.160 |
Why?
|
| Practice Patterns, Physicians' | 2 | 2017 | 504 | 0.150 |
Why?
|
| Induction Chemotherapy | 1 | 2018 | 39 | 0.150 |
Why?
|
| Time | 1 | 1998 | 57 | 0.150 |
Why?
|
| Oncogene Proteins | 1 | 2018 | 35 | 0.150 |
Why?
|
| Chromosomal Proteins, Non-Histone | 1 | 2018 | 27 | 0.150 |
Why?
|
| Prednisone | 4 | 2008 | 104 | 0.150 |
Why?
|
| Medication Therapy Management | 1 | 2017 | 32 | 0.140 |
Why?
|
| Rituximab | 1 | 2017 | 61 | 0.140 |
Why?
|
| Alcohol Drinking | 2 | 2000 | 805 | 0.140 |
Why?
|
| Pain | 4 | 2010 | 472 | 0.140 |
Why?
|
| Vasculitis, Leukocytoclastic, Cutaneous | 1 | 1996 | 4 | 0.130 |
Why?
|
| Biomarkers | 7 | 2019 | 1593 | 0.130 |
Why?
|
| Cat-Scratch Disease | 1 | 1996 | 10 | 0.130 |
Why?
|
| Joint Diseases | 2 | 1996 | 37 | 0.120 |
Why?
|
| Symptom Flare Up | 3 | 2019 | 20 | 0.120 |
Why?
|
| Magnetic Resonance Imaging | 3 | 1997 | 2223 | 0.120 |
Why?
|
| Risk Factors | 10 | 2019 | 5731 | 0.120 |
Why?
|
| Skin | 3 | 2010 | 451 | 0.110 |
Why?
|
| Lipoma | 1 | 1994 | 24 | 0.110 |
Why?
|
| Killer Cells, Natural | 2 | 2004 | 94 | 0.110 |
Why?
|
| Catastrophization | 1 | 2013 | 4 | 0.110 |
Why?
|
| Infant | 10 | 2018 | 2891 | 0.110 |
Why?
|
| Knee Joint | 1 | 1994 | 115 | 0.110 |
Why?
|
| Adalimumab | 2 | 2019 | 16 | 0.110 |
Why?
|
| Self Efficacy | 1 | 2014 | 199 | 0.110 |
Why?
|
| Electronic Health Records | 1 | 2016 | 374 | 0.110 |
Why?
|
| Psychometrics | 2 | 2013 | 514 | 0.100 |
Why?
|
| Quality Assurance, Health Care | 1 | 2013 | 177 | 0.100 |
Why?
|
| Adult | 21 | 2008 | 21403 | 0.100 |
Why?
|
| Case-Control Studies | 5 | 2018 | 1553 | 0.100 |
Why?
|
| Receptors, Tumor Necrosis Factor | 2 | 2006 | 32 | 0.100 |
Why?
|
| Predictive Value of Tests | 5 | 2019 | 1465 | 0.100 |
Why?
|
| Iontophoresis | 1 | 2011 | 7 | 0.100 |
Why?
|
| Syndrome | 5 | 2010 | 255 | 0.100 |
Why?
|
| Muscle, Skeletal | 2 | 2006 | 396 | 0.100 |
Why?
|
| Temporomandibular Joint | 1 | 2011 | 18 | 0.100 |
Why?
|
| Temporomandibular Joint Disorders | 1 | 2011 | 20 | 0.100 |
Why?
|
| Chronic Disease | 7 | 2010 | 1330 | 0.100 |
Why?
|
| Self Concept | 2 | 2010 | 132 | 0.100 |
Why?
|
| Hydroxychloroquine | 2 | 2008 | 14 | 0.090 |
Why?
|
| Dexamethasone | 1 | 2011 | 150 | 0.090 |
Why?
|
| T-Lymphocytes | 5 | 2007 | 597 | 0.090 |
Why?
|
| Leukocyte-Adhesion Deficiency Syndrome | 1 | 2010 | 1 | 0.090 |
Why?
|
| Absenteeism | 2 | 2010 | 27 | 0.090 |
Why?
|
| Hypertension, Pulmonary | 1 | 2013 | 232 | 0.090 |
Why?
|
| Fatal Outcome | 1 | 2010 | 164 | 0.090 |
Why?
|
| Recurrence | 2 | 2010 | 948 | 0.090 |
Why?
|
| Interleukin-4 | 2 | 2001 | 69 | 0.090 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2011 | 234 | 0.090 |
Why?
|
| Risk Assessment | 3 | 2008 | 2007 | 0.090 |
Why?
|
| Pediatrics | 3 | 2017 | 341 | 0.080 |
Why?
|
| Time Factors | 8 | 2019 | 4655 | 0.080 |
Why?
|
| Muscular Diseases | 2 | 2006 | 41 | 0.080 |
Why?
|
| Caregivers | 2 | 2003 | 365 | 0.080 |
Why?
|
| Muscles | 2 | 2005 | 158 | 0.080 |
Why?
|
| Prospective Studies | 5 | 2018 | 3705 | 0.080 |
Why?
|
| Motor Activity | 2 | 2010 | 621 | 0.080 |
Why?
|
| Macrophage Activation Syndrome | 1 | 2008 | 3 | 0.080 |
Why?
|
| Occupations | 1 | 2008 | 27 | 0.080 |
Why?
|
| Parents | 4 | 2004 | 312 | 0.080 |
Why?
|
| Logistic Models | 3 | 2007 | 1420 | 0.080 |
Why?
|
| Analysis of Variance | 3 | 2013 | 1040 | 0.080 |
Why?
|
| Activities of Daily Living | 5 | 2013 | 319 | 0.080 |
Why?
|
| Societies, Medical | 1 | 2011 | 403 | 0.080 |
Why?
|
| Consensus | 2 | 2019 | 211 | 0.080 |
Why?
|
| Coronary Aneurysm | 1 | 1988 | 19 | 0.080 |
Why?
|
| Follow-Up Studies | 6 | 2010 | 3259 | 0.080 |
Why?
|
| Mucocutaneous Lymph Node Syndrome | 1 | 1988 | 20 | 0.080 |
Why?
|
| Iridocyclitis | 3 | 1992 | 3 | 0.080 |
Why?
|
| Child Behavior Disorders | 1 | 2008 | 69 | 0.080 |
Why?
|
| Facial Paralysis | 1 | 1988 | 25 | 0.080 |
Why?
|
| Health Personnel | 1 | 2011 | 286 | 0.080 |
Why?
|
| Peer Group | 3 | 2008 | 104 | 0.070 |
Why?
|
| HLA-DR4 Antigen | 2 | 2005 | 11 | 0.070 |
Why?
|
| Reproducibility of Results | 7 | 2008 | 2077 | 0.070 |
Why?
|
| Antigens, Differentiation, Myelomonocytic | 1 | 2007 | 30 | 0.070 |
Why?
|
| Interpersonal Relations | 3 | 2010 | 209 | 0.070 |
Why?
|
| Proteinuria | 1 | 2007 | 136 | 0.070 |
Why?
|
| Interleukin-2 Receptor alpha Subunit | 1 | 2007 | 32 | 0.070 |
Why?
|
| Spinal Diseases | 2 | 1998 | 53 | 0.070 |
Why?
|
| Leukocytes, Mononuclear | 2 | 2004 | 124 | 0.070 |
Why?
|
| Cost of Illness | 1 | 2008 | 206 | 0.070 |
Why?
|
| Product Surveillance, Postmarketing | 1 | 2006 | 17 | 0.070 |
Why?
|
| Kidney Diseases | 1 | 2009 | 307 | 0.070 |
Why?
|
| Private Sector | 1 | 2006 | 19 | 0.070 |
Why?
|
| Autoimmune Diseases | 2 | 2004 | 186 | 0.070 |
Why?
|
| Prognosis | 3 | 2009 | 2093 | 0.070 |
Why?
|
| Bone Resorption | 1 | 2006 | 64 | 0.070 |
Why?
|
| Interleukin 1 Receptor Antagonist Protein | 1 | 2006 | 17 | 0.070 |
Why?
|
| Abatacept | 1 | 2006 | 17 | 0.070 |
Why?
|
| Receptors, Interleukin-1 | 1 | 2006 | 18 | 0.070 |
Why?
|
| Sialoglycoproteins | 1 | 2006 | 24 | 0.070 |
Why?
|
| Receptors, Antigen, T-Cell, alpha-beta | 2 | 1998 | 29 | 0.070 |
Why?
|
| Synovial Membrane | 4 | 1998 | 23 | 0.070 |
Why?
|
| Antigens, CD | 1 | 2007 | 230 | 0.070 |
Why?
|
| Isoxazoles | 1 | 2006 | 22 | 0.070 |
Why?
|
| Crohn Disease | 1 | 1986 | 38 | 0.070 |
Why?
|
| Immunoconjugates | 1 | 2006 | 26 | 0.070 |
Why?
|
| Testis | 1 | 2006 | 37 | 0.070 |
Why?
|
| Interleukin-1 | 1 | 2006 | 86 | 0.070 |
Why?
|
| Colitis, Ulcerative | 1 | 1986 | 53 | 0.070 |
Why?
|
| Patient Compliance | 2 | 2007 | 402 | 0.070 |
Why?
|
| Receptors, Cell Surface | 1 | 2007 | 248 | 0.070 |
Why?
|
| Extremities | 2 | 2004 | 49 | 0.060 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2008 | 627 | 0.060 |
Why?
|
| Proteomics | 1 | 2007 | 246 | 0.060 |
Why?
|
| Bone Density | 1 | 2006 | 159 | 0.060 |
Why?
|
| Ovary | 1 | 2006 | 99 | 0.060 |
Why?
|
| Anxiety | 1 | 2008 | 422 | 0.060 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2006 | 151 | 0.060 |
Why?
|
| Immunologic Deficiency Syndromes | 1 | 2004 | 13 | 0.060 |
Why?
|
| Medication Adherence | 1 | 2008 | 335 | 0.060 |
Why?
|
| Financing, Personal | 1 | 2004 | 17 | 0.060 |
Why?
|
| Peptides, Cyclic | 1 | 2005 | 35 | 0.060 |
Why?
|
| Viral Envelope Proteins | 1 | 2004 | 43 | 0.060 |
Why?
|
| Gastrointestinal Diseases | 1 | 2005 | 107 | 0.060 |
Why?
|
| Genes, MHC Class II | 2 | 1996 | 29 | 0.060 |
Why?
|
| Spondylarthropathies | 1 | 2004 | 1 | 0.060 |
Why?
|
| Fasciitis | 1 | 2004 | 30 | 0.060 |
Why?
|
| Cognition Disorders | 1 | 2007 | 342 | 0.060 |
Why?
|
| HLA Antigens | 3 | 1999 | 82 | 0.060 |
Why?
|
| Hypercalcemia | 1 | 2004 | 34 | 0.060 |
Why?
|
| Chemokines, CXC | 1 | 2004 | 16 | 0.060 |
Why?
|
| Cytomegalovirus | 1 | 2004 | 63 | 0.060 |
Why?
|
| Panniculitis | 1 | 2004 | 7 | 0.060 |
Why?
|
| Eosinophilia | 1 | 2004 | 47 | 0.060 |
Why?
|
| Lymphoma, T-Cell, Cutaneous | 1 | 2004 | 10 | 0.060 |
Why?
|
| Membrane Proteins | 1 | 2008 | 617 | 0.060 |
Why?
|
| Health Status Indicators | 1 | 2004 | 117 | 0.060 |
Why?
|
| Lipocalin-2 | 3 | 2009 | 19 | 0.060 |
Why?
|
| Antibodies | 1 | 2005 | 241 | 0.060 |
Why?
|
| Pilot Projects | 4 | 2011 | 1342 | 0.060 |
Why?
|
| Alleles | 5 | 2008 | 386 | 0.060 |
Why?
|
| Child Rearing | 1 | 2003 | 8 | 0.060 |
Why?
|
| Polymorphism, Restriction Fragment Length | 2 | 1996 | 44 | 0.060 |
Why?
|
| Injections, Intra-Articular | 2 | 2019 | 15 | 0.060 |
Why?
|
| Immunoglobulin G | 1 | 2006 | 481 | 0.060 |
Why?
|
| Gene Expression | 2 | 2004 | 770 | 0.050 |
Why?
|
| Dasatinib | 1 | 2023 | 17 | 0.050 |
Why?
|
| Antibodies, Monoclonal | 1 | 2006 | 511 | 0.050 |
Why?
|
| Cross-Sectional Studies | 4 | 2013 | 2279 | 0.050 |
Why?
|
| Health Expenditures | 1 | 2004 | 170 | 0.050 |
Why?
|
| Calcium | 1 | 2006 | 929 | 0.050 |
Why?
|
| Neutrophils | 1 | 2023 | 204 | 0.050 |
Why?
|
| Retrospective Studies | 6 | 2013 | 7277 | 0.050 |
Why?
|
| Histocompatibility Antigens Class II | 2 | 1992 | 77 | 0.050 |
Why?
|
| Polymyositis | 1 | 2001 | 5 | 0.050 |
Why?
|
| Receptors, Chemokine | 1 | 2001 | 26 | 0.050 |
Why?
|
| ROC Curve | 3 | 2007 | 392 | 0.050 |
Why?
|
| Sensitivity and Specificity | 3 | 2007 | 1753 | 0.050 |
Why?
|
| Health Promotion | 1 | 2004 | 407 | 0.050 |
Why?
|
| Life Tables | 2 | 2018 | 29 | 0.050 |
Why?
|
| Family | 1 | 2003 | 293 | 0.050 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2001 | 126 | 0.050 |
Why?
|
| Cohort Studies | 4 | 2013 | 2358 | 0.050 |
Why?
|
| United States | 5 | 2017 | 7367 | 0.050 |
Why?
|
| HLA-B27 Antigen | 2 | 1999 | 4 | 0.050 |
Why?
|
| Midwestern United States | 1 | 2000 | 36 | 0.040 |
Why?
|
| Interferon-gamma | 1 | 2001 | 241 | 0.040 |
Why?
|
| Phosphorylation | 1 | 2023 | 1200 | 0.040 |
Why?
|
| Diagnosis, Differential | 3 | 2004 | 1140 | 0.040 |
Why?
|
| Skin Neoplasms | 1 | 2004 | 375 | 0.040 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2001 | 226 | 0.040 |
Why?
|
| Preventive Health Services | 1 | 2000 | 86 | 0.040 |
Why?
|
| Administration, Ophthalmic | 1 | 2019 | 3 | 0.040 |
Why?
|
| Maintenance Chemotherapy | 1 | 2019 | 10 | 0.040 |
Why?
|
| Psychiatric Status Rating Scales | 2 | 2013 | 782 | 0.040 |
Why?
|
| Polymerase Chain Reaction | 4 | 2008 | 492 | 0.040 |
Why?
|
| Mycobacterium chelonae | 1 | 1998 | 9 | 0.040 |
Why?
|
| Skin Diseases, Bacterial | 1 | 1998 | 17 | 0.040 |
Why?
|
| Spondylitis | 1 | 1998 | 1 | 0.040 |
Why?
|
| Observer Variation | 3 | 2007 | 330 | 0.040 |
Why?
|
| Arthralgia | 2 | 2011 | 30 | 0.040 |
Why?
|
| Mycobacterium Infections, Nontuberculous | 1 | 1998 | 37 | 0.040 |
Why?
|
| Facial Hemiatrophy | 1 | 1997 | 1 | 0.040 |
Why?
|
| Nephrotic Syndrome | 1 | 1998 | 61 | 0.040 |
Why?
|
| Cytokines | 2 | 2001 | 866 | 0.040 |
Why?
|
| Flow Cytometry | 3 | 2004 | 489 | 0.040 |
Why?
|
| Aspartate Aminotransferases | 1 | 1997 | 87 | 0.040 |
Why?
|
| Disease Resistance | 1 | 2017 | 3 | 0.040 |
Why?
|
| Serum Albumin | 1 | 1997 | 104 | 0.040 |
Why?
|
| Biological Therapy | 1 | 2017 | 8 | 0.040 |
Why?
|
| Alanine Transaminase | 1 | 1997 | 137 | 0.040 |
Why?
|
| Schools | 2 | 2010 | 156 | 0.040 |
Why?
|
| Double-Blind Method | 4 | 2006 | 1738 | 0.040 |
Why?
|
| Lymphotoxin-alpha | 1 | 1996 | 9 | 0.040 |
Why?
|
| Spondylitis, Ankylosing | 1 | 1996 | 10 | 0.030 |
Why?
|
| Inflammation | 1 | 2023 | 1030 | 0.030 |
Why?
|
| Radiography | 1 | 1998 | 572 | 0.030 |
Why?
|
| Mixed Connective Tissue Disease | 1 | 1996 | 9 | 0.030 |
Why?
|
| HLA-DR Antigens | 2 | 1995 | 41 | 0.030 |
Why?
|
| Proportional Hazards Models | 1 | 2018 | 792 | 0.030 |
Why?
|
| Chemical and Drug Induced Liver Injury | 1 | 1997 | 131 | 0.030 |
Why?
|
| Cysteine Endopeptidases | 1 | 1996 | 39 | 0.030 |
Why?
|
| Fibrosis | 1 | 1997 | 371 | 0.030 |
Why?
|
| Longitudinal Studies | 3 | 2009 | 1054 | 0.030 |
Why?
|
| Registries | 2 | 2013 | 733 | 0.030 |
Why?
|
| Cats | 1 | 1996 | 292 | 0.030 |
Why?
|
| Patient Education as Topic | 1 | 1998 | 425 | 0.030 |
Why?
|
| Body Mass Index | 1 | 1999 | 867 | 0.030 |
Why?
|
| Educational Status | 2 | 2008 | 273 | 0.030 |
Why?
|
| Magnetic Resonance Spectroscopy | 2 | 2005 | 346 | 0.030 |
Why?
|
| Gene Frequency | 3 | 2008 | 207 | 0.030 |
Why?
|
| Young Adult | 3 | 2011 | 5717 | 0.030 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 1995 | 135 | 0.030 |
Why?
|
| Immunoglobulins, Intravenous | 1 | 1994 | 52 | 0.030 |
Why?
|
| Lymph Nodes | 1 | 1996 | 258 | 0.030 |
Why?
|
| Clinical Trials as Topic | 1 | 1998 | 848 | 0.030 |
Why?
|
| CD56 Antigen | 2 | 2004 | 3 | 0.030 |
Why?
|
| Pore Forming Cytotoxic Proteins | 2 | 2004 | 8 | 0.030 |
Why?
|
| Perforin | 2 | 2004 | 12 | 0.030 |
Why?
|
| Cytotoxicity, Immunologic | 2 | 2004 | 66 | 0.030 |
Why?
|
| Molecular Sequence Data | 4 | 1998 | 1447 | 0.030 |
Why?
|
| Mass Screening | 1 | 2019 | 843 | 0.030 |
Why?
|
| Proteins | 1 | 1996 | 474 | 0.030 |
Why?
|
| Palpation | 1 | 2012 | 21 | 0.030 |
Why?
|
| Facial Pain | 1 | 2011 | 8 | 0.020 |
Why?
|
| Administration, Cutaneous | 1 | 2011 | 56 | 0.020 |
Why?
|
| Ohio | 1 | 2011 | 64 | 0.020 |
Why?
|
| Clone Cells | 3 | 1998 | 67 | 0.020 |
Why?
|
| CD8-Positive T-Lymphocytes | 2 | 2004 | 266 | 0.020 |
Why?
|
| Pain Threshold | 1 | 2012 | 55 | 0.020 |
Why?
|
| snRNP Core Proteins | 2 | 2004 | 5 | 0.020 |
Why?
|
| Membrane Glycoproteins | 2 | 2004 | 370 | 0.020 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2008 | 786 | 0.020 |
Why?
|
| Range of Motion, Articular | 1 | 2011 | 139 | 0.020 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2004 | 468 | 0.020 |
Why?
|
| Hospitals, Pediatric | 1 | 2011 | 114 | 0.020 |
Why?
|
| Autoantigens | 2 | 2004 | 91 | 0.020 |
Why?
|
| Ibuprofen | 1 | 1990 | 30 | 0.020 |
Why?
|
| Macrophages | 2 | 2007 | 647 | 0.020 |
Why?
|
| Leg | 2 | 2004 | 191 | 0.020 |
Why?
|
| Psychology, Adolescent | 1 | 2010 | 38 | 0.020 |
Why?
|
| Biomechanical Phenomena | 1 | 2011 | 368 | 0.020 |
Why?
|
| Social Isolation | 1 | 2010 | 40 | 0.020 |
Why?
|
| Chronic Pain | 1 | 2012 | 110 | 0.020 |
Why?
|
| Schizophrenic Psychology | 1 | 2010 | 53 | 0.020 |
Why?
|
| Serum Amyloid P-Component | 1 | 1989 | 4 | 0.020 |
Why?
|
| RNA, Messenger | 3 | 2001 | 1664 | 0.020 |
Why?
|
| Amino Acid Sequence | 3 | 1998 | 1083 | 0.020 |
Why?
|
| Amyloidosis | 1 | 1989 | 48 | 0.020 |
Why?
|
| Substance-Related Disorders | 1 | 1998 | 1242 | 0.020 |
Why?
|
| Creatinine | 1 | 2009 | 243 | 0.020 |
Why?
|
| Monitoring, Physiologic | 1 | 2010 | 219 | 0.020 |
Why?
|
| Haplotypes | 3 | 1995 | 174 | 0.020 |
Why?
|
| Disease Susceptibility | 3 | 1996 | 179 | 0.020 |
Why?
|
| Axillary Artery | 1 | 1988 | 6 | 0.020 |
Why?
|
| Genetic Association Studies | 1 | 2008 | 103 | 0.020 |
Why?
|
| Outpatient Clinics, Hospital | 1 | 2008 | 69 | 0.020 |
Why?
|
| Interview, Psychological | 1 | 2008 | 113 | 0.020 |
Why?
|
| Monocytes | 1 | 1989 | 210 | 0.020 |
Why?
|
| Recovery of Function | 1 | 2011 | 506 | 0.020 |
Why?
|
| Sex Distribution | 1 | 2008 | 274 | 0.020 |
Why?
|
| Aneurysm | 1 | 1988 | 53 | 0.020 |
Why?
|
| Protein Array Analysis | 1 | 2007 | 32 | 0.020 |
Why?
|
| Pharmacies | 1 | 2007 | 18 | 0.020 |
Why?
|
| Connective Tissue Diseases | 1 | 1987 | 18 | 0.020 |
Why?
|
| Chi-Square Distribution | 1 | 2008 | 546 | 0.020 |
Why?
|
| Soft Tissue Neoplasms | 1 | 1987 | 28 | 0.020 |
Why?
|
| Brain | 1 | 1997 | 2176 | 0.020 |
Why?
|
| Ferritins | 1 | 2007 | 49 | 0.020 |
Why?
|
| Education, Special | 1 | 1986 | 5 | 0.020 |
Why?
|
| Middle Aged | 5 | 2008 | 21147 | 0.020 |
Why?
|
| Infarction | 1 | 2006 | 17 | 0.020 |
Why?
|
| Remission Induction | 1 | 2006 | 111 | 0.020 |
Why?
|
| Fluorescent Antibody Technique, Direct | 1 | 2006 | 21 | 0.020 |
Why?
|
| Acute Disease | 1 | 2008 | 658 | 0.020 |
Why?
|
| Depressive Disorder | 1 | 2010 | 621 | 0.020 |
Why?
|
| Disease Progression | 1 | 2009 | 1038 | 0.020 |
Why?
|
| Betaine | 1 | 2005 | 3 | 0.020 |
Why?
|
| Methylamines | 1 | 2005 | 4 | 0.020 |
Why?
|
| Capillaries | 1 | 2006 | 105 | 0.020 |
Why?
|
| Choline | 1 | 2005 | 14 | 0.020 |
Why?
|
| Body Composition | 1 | 2006 | 119 | 0.020 |
Why?
|
| Creatine | 1 | 2005 | 30 | 0.020 |
Why?
|
| Bone and Bones | 1 | 2006 | 145 | 0.020 |
Why?
|
| Neuropsychological Tests | 1 | 2007 | 517 | 0.020 |
Why?
|
| Ribonucleoprotein, U1 Small Nuclear | 1 | 2004 | 1 | 0.020 |
Why?
|
| Vaccines, Subunit | 1 | 2004 | 10 | 0.020 |
Why?
|
| Rheumatoid Factor | 1 | 2005 | 21 | 0.020 |
Why?
|
| Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2007 | 306 | 0.020 |
Why?
|
| Ribonucleoproteins, Small Nuclear | 1 | 2004 | 11 | 0.020 |
Why?
|
| Vaccines, Synthetic | 1 | 2004 | 19 | 0.020 |
Why?
|
| Glycine | 1 | 2005 | 89 | 0.020 |
Why?
|
| Cytotoxicity Tests, Immunologic | 1 | 2004 | 22 | 0.020 |
Why?
|
| Lymphohistiocytosis, Hemophagocytic | 1 | 2004 | 9 | 0.020 |
Why?
|
| Granzymes | 1 | 2004 | 19 | 0.020 |
Why?
|
| K562 Cells | 1 | 2004 | 44 | 0.020 |
Why?
|
| Raynaud Disease | 1 | 1985 | 24 | 0.020 |
Why?
|
| Health | 1 | 2004 | 26 | 0.020 |
Why?
|
| Bleomycin | 1 | 1985 | 67 | 0.020 |
Why?
|
| Proxy | 1 | 2004 | 8 | 0.020 |
Why?
|
| Siblings | 1 | 2005 | 34 | 0.020 |
Why?
|
| Serine Endopeptidases | 1 | 2004 | 50 | 0.020 |
Why?
|
| Immunoenzyme Techniques | 1 | 2004 | 196 | 0.020 |
Why?
|
| Models, Economic | 1 | 2004 | 69 | 0.020 |
Why?
|
| Coculture Techniques | 1 | 2004 | 147 | 0.020 |
Why?
|
| Infant, Newborn | 2 | 1999 | 2455 | 0.010 |
Why?
|
| Blood Chemical Analysis | 1 | 2004 | 43 | 0.010 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2004 | 282 | 0.010 |
Why?
|
| Immunoblotting | 1 | 2004 | 254 | 0.010 |
Why?
|
| Incidence | 1 | 2008 | 1603 | 0.010 |
Why?
|
| Comorbidity | 1 | 2008 | 1426 | 0.010 |
Why?
|
| Aging | 1 | 2010 | 911 | 0.010 |
Why?
|
| Immunohistochemistry | 2 | 1996 | 1174 | 0.010 |
Why?
|
| Head | 1 | 2004 | 59 | 0.010 |
Why?
|
| Face | 1 | 2004 | 46 | 0.010 |
Why?
|
| Antibodies, Antinuclear | 2 | 1996 | 171 | 0.010 |
Why?
|
| Dietary Supplements | 1 | 2006 | 332 | 0.010 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2004 | 195 | 0.010 |
Why?
|
| Base Sequence | 2 | 1996 | 1015 | 0.010 |
Why?
|
| Cells, Cultured | 2 | 2004 | 2673 | 0.010 |
Why?
|
| Reference Values | 1 | 2004 | 579 | 0.010 |
Why?
|
| Movement | 1 | 2004 | 179 | 0.010 |
Why?
|
| Joints | 1 | 2003 | 30 | 0.010 |
Why?
|
| Neovascularization, Pathologic | 1 | 2004 | 183 | 0.010 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2004 | 320 | 0.010 |
Why?
|
| Genes | 2 | 1993 | 86 | 0.010 |
Why?
|
| Trans-Activators | 1 | 2004 | 237 | 0.010 |
Why?
|
| DNA Mutational Analysis | 1 | 2003 | 159 | 0.010 |
Why?
|
| Feasibility Studies | 1 | 2004 | 652 | 0.010 |
Why?
|
| Cell Proliferation | 1 | 2007 | 1174 | 0.010 |
Why?
|
| T-Lymphocytes, Cytotoxic | 1 | 2003 | 79 | 0.010 |
Why?
|
| Family Health | 1 | 2003 | 83 | 0.010 |
Why?
|
| Collagen Diseases | 1 | 1982 | 2 | 0.010 |
Why?
|
| Patella | 1 | 1982 | 14 | 0.010 |
Why?
|
| Cartilage Diseases | 1 | 1982 | 10 | 0.010 |
Why?
|
| Psychophysiologic Disorders | 1 | 1982 | 20 | 0.010 |
Why?
|
| Genotype | 2 | 1996 | 786 | 0.010 |
Why?
|
| Rheumatic Fever | 1 | 1981 | 2 | 0.010 |
Why?
|
| Vitamin D | 1 | 2006 | 516 | 0.010 |
Why?
|
| Gene Expression Profiling | 1 | 2004 | 498 | 0.010 |
Why?
|
| Health Care Costs | 1 | 2004 | 346 | 0.010 |
Why?
|
| Indiana | 1 | 1981 | 35 | 0.010 |
Why?
|
| Receptors, CCR4 | 1 | 2001 | 2 | 0.010 |
Why?
|
| Chemokine CCL17 | 1 | 2001 | 2 | 0.010 |
Why?
|
| Chemokine CCL22 | 1 | 2001 | 6 | 0.010 |
Why?
|
| Chemokines, CC | 1 | 2001 | 18 | 0.010 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2003 | 186 | 0.010 |
Why?
|
| DNA Probes | 2 | 1992 | 57 | 0.010 |
Why?
|
| Immunophenotyping | 1 | 2001 | 110 | 0.010 |
Why?
|
| Bone Neoplasms | 1 | 1982 | 100 | 0.010 |
Why?
|
| Physical Examination | 1 | 1982 | 152 | 0.010 |
Why?
|
| Attitude to Health | 1 | 2003 | 403 | 0.010 |
Why?
|
| Ligands | 1 | 2001 | 317 | 0.010 |
Why?
|
| Methylprednisolone | 1 | 1980 | 99 | 0.010 |
Why?
|
| HLA-DR6 Antigen | 1 | 1999 | 1 | 0.010 |
Why?
|
| HLA-DR5 Antigen | 1 | 1999 | 3 | 0.010 |
Why?
|
| HLA-DR1 Antigen | 1 | 1999 | 2 | 0.010 |
Why?
|
| Social Support | 1 | 2003 | 423 | 0.010 |
Why?
|
| Sampling Studies | 1 | 1998 | 80 | 0.010 |
Why?
|
| Animals | 1 | 1996 | 20881 | 0.010 |
Why?
|
| Antigens | 1 | 1998 | 90 | 0.010 |
Why?
|
| Patients | 1 | 1997 | 69 | 0.010 |
Why?
|
| CD4-CD8 Ratio | 1 | 1996 | 5 | 0.010 |
Why?
|
| Receptors, Antigen, T-Cell, gamma-delta | 1 | 1996 | 8 | 0.010 |
Why?
|
| CD3 Complex | 1 | 1996 | 35 | 0.010 |
Why?
|
| Ribonucleoproteins | 1 | 1996 | 19 | 0.010 |
Why?
|
| Age of Onset | 1 | 1996 | 188 | 0.010 |
Why?
|
| Oligonucleotide Probes | 1 | 1996 | 35 | 0.010 |
Why?
|
| Stress, Psychological | 1 | 2003 | 824 | 0.010 |
Why?
|
| Major Histocompatibility Complex | 1 | 1996 | 34 | 0.010 |
Why?
|
| HLA-DR Serological Subtypes | 1 | 1995 | 2 | 0.010 |
Why?
|
| Arthritis, Rheumatoid | 1 | 1996 | 157 | 0.010 |
Why?
|
| DNA, Complementary | 1 | 1995 | 251 | 0.010 |
Why?
|
| Lymphocyte Activation | 1 | 1996 | 397 | 0.010 |
Why?
|
| Signal Transduction | 1 | 2004 | 2689 | 0.010 |
Why?
|
| Age Factors | 1 | 1999 | 1864 | 0.010 |
Why?
|
| Gene Rearrangement, beta-Chain T-Cell Antigen Receptor | 1 | 1993 | 3 | 0.010 |
Why?
|
| Prevalence | 1 | 1998 | 1619 | 0.010 |
Why?
|
| Oligodeoxyribonucleotides | 1 | 1993 | 35 | 0.010 |
Why?
|
| Physicians | 1 | 1997 | 324 | 0.010 |
Why?
|
| Sequence Alignment | 1 | 1993 | 165 | 0.010 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 1993 | 231 | 0.010 |
Why?
|
| Phenotype | 1 | 1996 | 947 | 0.010 |
Why?
|
| HLA-DRB1 Chains | 1 | 1992 | 21 | 0.010 |
Why?
|
| Gene Amplification | 1 | 1992 | 71 | 0.010 |
Why?
|
| Immunogenetics | 1 | 1992 | 8 | 0.010 |
Why?
|
| Genetic Markers | 1 | 1992 | 144 | 0.010 |
Why?
|
| HLA-D Antigens | 1 | 1992 | 20 | 0.010 |
Why?
|
| Suspensions | 1 | 1990 | 11 | 0.010 |
Why?
|
| Gene Expression Regulation | 1 | 1996 | 1293 | 0.010 |
Why?
|
| Deoxyribonuclease HpaII | 1 | 1989 | 1 | 0.010 |
Why?
|
| Deoxyribonucleases, Type II Site-Specific | 1 | 1989 | 8 | 0.010 |
Why?
|
| Chromosomes, Human, Pair 1 | 1 | 1989 | 28 | 0.010 |
Why?
|
| Aspirin | 1 | 1990 | 295 | 0.010 |
Why?
|
| Cell Division | 1 | 1989 | 541 | 0.000 |
Why?
|
| Kinetics | 1 | 1989 | 1047 | 0.000 |
Why?
|
| DNA | 1 | 1989 | 597 | 0.000 |
Why?
|
| Child Health Services | 1 | 1986 | 50 | 0.000 |
Why?
|
| School Health Services | 1 | 1986 | 72 | 0.000 |
Why?
|
| Physician's Role | 1 | 1986 | 116 | 0.000 |
Why?
|
| History, 20th Century | 1 | 1986 | 248 | 0.000 |
Why?
|
| Disabled Persons | 1 | 1986 | 94 | 0.000 |
Why?
|
| Mesonephroma | 1 | 1985 | 3 | 0.000 |
Why?
|
| Dactinomycin | 1 | 1985 | 31 | 0.000 |
Why?
|
| Vaginal Neoplasms | 1 | 1985 | 21 | 0.000 |
Why?
|
| Vinblastine | 1 | 1985 | 40 | 0.000 |
Why?
|
| Cisplatin | 1 | 1985 | 192 | 0.000 |
Why?
|
| Doxorubicin | 1 | 1985 | 231 | 0.000 |
Why?
|
| Epilepsy, Tonic-Clonic | 1 | 1980 | 9 | 0.000 |
Why?
|
| Coma | 1 | 1980 | 17 | 0.000 |
Why?
|
| Anemia, Hemolytic | 1 | 1980 | 37 | 0.000 |
Why?
|
| Injections, Intravenous | 1 | 1980 | 215 | 0.000 |
Why?
|
| Thrombocytopenia | 1 | 1980 | 122 | 0.000 |
Why?
|
| Drug Administration Schedule | 1 | 1980 | 567 | 0.000 |
Why?
|
| Tomography, X-Ray Computed | 1 | 1987 | 2324 | 0.000 |
Why?
|
| Aged | 1 | 1989 | 14862 | 0.000 |
Why?
|